MEDICAL BIO WARFARE DEFENSE PLAN 18 MAR 91

File: 970107_sep96_decls57_0005.txt
Page: 0005
Total Pages: 10

Subject: MEDICAL BIO WARFARE DEFENSE PLAN  18 MAR 91                     

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003202

Folder Title: MEDICAL BIOLOGICAL WARFARE - BW- DEFENSE PLAN                                                   

Document Number:          1

Folder Seq  #:         25




                                        UNCLASSIFIED





         may require repackaging in new multi-dose vials which would create
         logistical and administrative issues. Storage in bulk is recommend
         for a large percentage of these products.

         6. (U) Maintain industrial base for vaccine and antitoxin
         production by establishing annual requirements in para 3. Also
         maintain CONUS industrial base for Cipro (ciprofloxadin) and
         doxycycline antibiotic production to ensure treatment capability
         against anthrax. Industrial base for other vaccines and
         biologicals should be maintained.

         7. (U) Finalize the TRADOC boarding process for the Theater Army
         Medical Laboratory. This laboratory id specifically designed to
         identify BW and chemical warfare agents used against U.S. Forces in
         the theater of operations and provides vital information in the
         diagnosis and treatment of BW and CW casualties.

         8.      Establish a MOU between Department of Defense
                                             exchange suspected BW samples
         for double verification of BW attack on either country's forces.
         Analysis results plus other supportive data would provide solid
         evidence and an irrefutable basis for retaliation against opposing
         force(s) using BW agents. U.S.               have internationally
         recognized laboratories for definitive identification of BW
         agents. Confirmatory results from either labs of BW agent present
         is definitive proof. Confirmatory results from both labs of BW
         agent present is irrefutable proof before the international
         community.

         9. (U) Make vaccines and antitoxins available to select allies
         through Foreign Military Sales to avoid future geopolitical
         vaccination issues and to develop a deterrence against the use of
         such BW agents in future wars.

tions to request BW vaccines from U.S.
         to establish their contingency stockpile.

             b. (U) Select allies should be offered the opportunity to
         obtain BW vaccines from U.S. to enhance their readiness posture.

             C. (U) This initiative would help to maintain the vaccine
         production industrial base in CONUS and address future potential
         geopolitical issues as those encountered in operation Desert
         Shield.









                                            3


                                        UNCLASSIFIED
                                        lQr.i2Dr.-@ '
                                        '%)LUJIL ,

Document 10 f:/Week-36/BX003202/MEDICAL BIOLOGICAL WARFARE - BW- DEFENSE PLAN/medical bio warfare defense plan 18 mar 91:01029715474558
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003202
Unit = OTSG
Parent Organization = HSC
Folder Title = MEDICAL BIOLOGICAL WARFARE - BW- DEFENSE PLAN
Folder Seq # = 25
Subject = MEDICAL BIO WARFARE DEFENSE PLAN 18 MAR 91
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997